XELOX-C方案与XELOX方案对胃癌患者的疗效及安全性分析

摘要

目的研究对比XELOX-C（卡培他滨联合奥沙利铂、塞来昔布）方案和XELOX （卡培他滨联合奥沙利铂）方案对胃癌病患的治疗效果以及安全性。方法选择胃癌病患126例，以数字法随机分为观察组和对照组各63例。观察组采用XELOX-C方案治疗，对照组采用XELOX方案治疗。对比两组治疗效果以及治疗后的毒副反应，分析安全性。结果观察组治疗后CR、PR病患比例显著高于对照组，其中观察组治疗的总有效率为79.37%（50/63），显著高于对照组的46.03%（29/63）；观察组治疗后复发转移率、骨髓抑制总发生率均显著低于对照组，而生活质量改善比率高于对照组；观察组治疗后出现恶心呕吐等毒副反应比例均显著低于对照组，两组治疗前环氧合酶（COX-2）和VEGF水平对比无差异，分别治疗后观察组COX-2和VEGF水平均显著低于对照组，差异均有统计学意义（均P＜0.05）。结论 XELOX-C方案相对于XELOX方案对胃癌病患具有更好的治疗效果，更少的毒副反应，因此XELOX-C方案在临床上具有更高的应用价值，值得推广。%Objective To explore the correlation of XELOX-C (capecitabine plus oxaliplatin, celecoxib) and XELOX (capecitabine plus oxaliplatin) on gastric cancer patient treatment effect and safety. Methods Chose patients with gastric carcinoma in 126 cases, with digital method were randomly divided into observation group and control group with 63 cases in each group. The observation group received XELOX-C treatment, the control group was treated with XELOX regimen in the treatment of adverse reactions. The comparison of two groups of treatment and after treatment, explore the safety.Results The observation group after treatment CR, PR patients was significantly higher than the control group, the observation group’s total effective rate was 79.37% (50/63), was significantly higher than the control group of 46.03% (29/63). The patients in the observation group of recurrence rate, the total incidence of bone marrow suppression was significantly lower than the control group, and the quality of life Improvement rate was higher than those of control group. And observe the treatment group after appear nausea, vomiting and other adverse reaction ratio were significantly lower than those in the control group. The two groups before treatment cyclooxygenase (COX-2) and VEGF levels compared with no difference, respectively after the treatment, the observation group, the expression of COX-2 and VEGF levels were significantly lower than those in the control group. Differences are statistically significant difference (P< 0.05).ConclusionXELOX-C compared with XELOX for gastric cancer patients has a better therapeutic effect, less adverse reaction, so XELOX-C in clinical on the has higher application value, worthy of promotion.